Publications by authors named "Ariel Teper"

Claim this Profile
A
A Phase IIa, Single-Blind, Placebo-Controlled, Parallel-Group Study to Assess Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Brensocatib in Adults with Cystic Fibrosis.
Michael W Konstan, James J Tolle, Emily DiMango, Patrick A Flume, Helen Usansky, Ariel Teper

Clin Pharmacokinet· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Broad Immunomodulatory Effects of the Dipeptidyl Peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW Trial.
Emma D Johnson, Merete B Long, Lidia Perea, Vivian H Shih, Carlos Fernandez, Ariel Teper

Am J Respir Crit Care Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.
James D Chalmers, Pierre-Régis Burgel, Charles L Daley, Anthony De Soyza, Charles S Haworth, Ariel Teper

N Engl J Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brensocatib in patients with bronchiectasis: subgroup analyses from the WILLOW trial.
James D Chalmers, Michael R Loebinger, Ariel Teper, Pamela J McShane, Carlos Fernandez

ERJ Open Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics.
James D Chalmers, Pierre-Régis Burgel, Charles L Daley, Anthony De Soyza, Charles S Haworth, Ariel Teper

ERJ Open Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis.
James D Chalmers, Mark L Metersky, Joseph Feliciano, Carlos Fernandez, Ariel Teper

ERJ Open Res· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of exacerbations on lung function, resource utilization, and productivity: results from an observational, prospective study in adults with uncontrolled asthma.
Juan Wisnivesky, Emily Federmann, Laurent Eckert, Erin West, Caroline Amand, Ariel Teper

J Asthma· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial.
David Cipolla, Jimin Zhang, Brice Korkmaz, James D Chalmers, Jessica Basso, Ariel Teper

Respir Res· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study.
Fraz A Ismat, Helen H Usansky, Raul Villa, Jun Zou, Ariel Teper

Adv Ther· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis.
James D Chalmers, Helen Usansky, Christopher M Rubino, Ariel Teper, Carlos Fernandez

Clin Pharmacokinet· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetic Evaluation of Single and Multiple Doses of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Healthy Japanese and White Adults.
Helen Usansky, Esther Yoon, Ariel Teper, Jun Zou, Carlos Fernandez

Clin Pharmacol Drug Dev· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma.
Jonathan Corren, Constance H Katelaris, Mario Castro, Jorge F Maspero, Linda B Ford, Ariel Teper

Eur Respir J· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST.
Jorge F Maspero, John Mark FitzGerald, Ian D Pavord, Megan S Rice, Jaman Maroni, Ariel Teper

Allergy· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function.
Ian D Pavord, Salman Siddiqui, Alberto Papi, Jonathan Corren, Lawrence D Sher, Ariel Teper

J Asthma Allergy· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis.
William W Busse, Jorge F Maspero, Yufang Lu, Jonathan Corren, Nicola A Hanania, Ariel Teper

Ann Allergy Asthma Immunol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study.
Yuji Tohda, Yoichi Nakamura, Takao Fujisawa, Motohiro Ebisawa, Kazuhiko Arima, Ariel Teper

Allergol Int· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis.
Jorge F Maspero, Constance H Katelaris, William W Busse, Mario Castro, Jonathan Corren, Ariel Teper

J Allergy Clin Immunol Pract· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma.
Jonathan Corren, Mario Castro, Thomas O'Riordan, Nicola A Hanania, Ian D Pavord, Ariel Teper

J Allergy Clin Immunol Pract· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma.
Mario Castro, Klaus F Rabe, Jonathan Corren, Ian D Pavord, Constance H Katelaris, Ariel Teper

ERJ Open Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history.
Jonathan Corren, Mario Castro, Linda B Ford, Jonathan A Bernstein, Shyamalie Jayawardena, Ariel Teper

Ann Allergy Asthma Immunol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma.
Jonathan Corren, Mario Castro, Pascal Chanez, Leonardo Fabbri, Vijay N Joish, Ariel Teper

Ann Allergy Asthma Immunol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma.
Steven F Weinstein, Rohit Katial, Shyamalie Jayawardena, Gianluca Pirozzi, Heribert Staudinger, Ariel Teper

J Allergy Clin Immunol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
Mario Castro, Jonathan Corren, Ian D Pavord, Jorge Maspero, Sally Wenzel, Ariel Teper

N Engl J Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.
Klaus F Rabe, Parameswaran Nair, Guy Brusselle, Jorge F Maspero, Mario Castro, Ariel Teper

N Engl J Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma.
William W Busse, Jorge F Maspero, Klaus F Rabe, Alberto Papi, Sally E Wenzel, Ariel Teper

Adv Ther· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis